Molecular monitoring to identify a threshold of CBFβ/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv(16) is likely

Haematologica

Volumn 89, Issue 4, 2004, Pages 495-497

  Martinelli, Giovanni ^a,b   Rondoni, Michela ^a   Buonamici, Silvia ^a   Ottaviani, Emanuela ^a   Piccaluga, Pier Paolo ^a   Malagola, Michele ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Inst Hematol/Med Oncol Seragnoli   (Italy)

Author keywords

AML; ASCT; CBF MYH11; Fludarabine; Inv(16); Quantitative RT PCR

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CBFBETA GENE; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FOLLOW UP; GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MINIMAL RESIDUAL DISEASE; MYH11 GENE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ADOLESCENT; ADULT; CHROMOSOMES, HUMAN, PAIR 16; FEMALE; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 2942716666     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia: analysis of 848 patients. Leukemia 2001;15:903-9.
2. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Medical Research Council Adult Leukemia Working Party. Blood 2001;98:1312-20.
3. Mrozek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2001;19:2482-92.
4. Martinelli G, Ottaviani E, Testoni N, Montefusco V, Pastano R, Tura S. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFβ/MYH11 transcript. Haematologica 2000;85:552-5.
5. Martinelli G, Ottaviani E, Buonamici S, Isidori A, Malagola M, Piccaluga P, et al. Two more inv(16) acute myeloid leukemia cases with infrequent CBFβ-MYH11 fusion transcript: clinical and molecular findings. Haematologica 2002;87:554-5.
6. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002;99:443-9.
7. Marcucci G, Caligiuri MA, Bloomfield CD. Defining the "absence" of the CBFβ/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood 1997;90:5022-4.
8. Marcucci G, Caligiuri MA, Döhner H, Archer KJ, Schlenk RF, Dohner K, et al. Quantification of CBFβ/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001;15:1072-80.
9. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E, et al. Assessment of minimal residual disease (MRD) in CBFβ/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002;16:1176-81.
10. Krauter J, Hoellge W, Wattjes MP, Nagel S, Heidenreich O, Bunjes D, et al. Detection and quantification of CBFβ/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer 2001;30:342-8.